Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S169000, C546S090000, C514S291000
Reexamination Certificate
active
07053104
ABSTRACT:
The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
REFERENCES:
patent: 3632581 (1972-01-01), Potoski et al.
patent: 4450167 (1984-05-01), Le Martret et al.
patent: 4933342 (1990-06-01), Takahashi et al.
patent: 5106976 (1992-04-01), Okabe et al.
patent: 2 050 074 (1970-10-01), None
patent: 27 28 248 (1977-06-01), None
patent: 0 002 066 (1979-05-01), None
patent: 0 407 192 (1991-01-01), None
patent: 0 694 599 (1996-01-01), None
patent: 7-179371 (1995-07-01), None
patent: 95/09159 (1995-04-01), None
patent: 96/05818 (1996-02-01), None
patent: 96/40641 (1996-12-01), None
patent: 97/02247 (1997-01-01), None
patent: 98/3900 (1998-09-01), None
patent: WO 98/50364 (1998-11-01), None
patent: 01/32632 (2001-05-01), None
patent: 01/32644 (2001-05-01), None
N.S. Kozlov et al, “Synthesis of adamantane-type beta-amino ketones”, XP002101994, abstract & Vestsi Akad. Navuk BSSR, Ser. Khim. Navuk, No. 1, (1991), pp. 60-65.
B. Prager et al. “Beilsteins Handbuch der Organischen Chemie, 9. Bd.”, (1926), Verlag Von Julius Springer Berlin, XP002101990, p. 114.
B. Prager et al. “Beilsteins Handbuch der Organischem Chemie, 12. Bd.”, (1929) Verlag Von Julius Springer Berlin XP002101991, p. 7.
V. Bruno et al., “Neuroprotective activity of the potent . . . ,” Neuropharmacology 38 (1999), pp. 199-207.
A. G. Chapman, “Glutamate and Epilepsy,” American Society for Nutritional Sciences, 2000, pp. 1043S-1045S.
A. Palucha et al., “On the role of metabotropic . . . ,” Polish Journal of Pharmacology, 2002, 54, pp. 581-586.
G. Battaglia et al., “Endogenous activation of mGlu5 . . . ,” The Journal of Neuroscience, Jan. 28, 2004, 24(4), pp. 828-835.
J. Schiefer et al., “The metabotropic glutamate receptor 5 antagonist MPEP . . . ,”Brain Research 1019 (2004), pp. 246-254.
M.O. Urban et al., “Role of metabotropic glutamate receptor subtype 5 . . . ,” Neuropharmacology, 44 (2003), pp. 983-993.
C.Z. Zhu et al., “Role of central and peripheral mGluR5 receptors . . . ,” Pain, 114 (2005), pp. 195-202.
J. Brodkin et al., “Reduced stress-induced hyperthermia . . . ,” European Journal of Neuroscience, vol. 16, 2002, pp. 2241-2244.
M. Pietraszek et al., “mGluR5, but not mGluR1, antagonist . . . ,” Neuropharmacology, 49 (2005), pp. 73-85.
M.J. Bradbury et al., “Metabotropic glutamate receptor 5 antagonist—induced . . . ,” Neuropharmacology, 44 (2003), pp. 562-572.
P. Gubellini et al., “Induction of corticostriatal LTP . . . ,” Neuropharmacology, 46, (2004), pp. 761-769.
E. Meli et al., “Activation of mGlul but not mGlu5 metabotropic . . . ,” Pharmacology, Biochemistry and Behavior, 73 (2002), pp. 439-446.
B.G. Lyeth et al., “Group I metabotropic glutamate antagonist . . . ,” Experimental Neurology, 169 (2001), pp. 191-199.
R.X. Moldrich et al. “Glutamate metabotropic receptors as targets . . . ,” European Journal of Pharmacology, 476 (2003), pp. 3-16.
I.A. Paul et al., “Glutamate and depression . . . ,” Analysis New York Academy of Sciences, 1003 (2003), pp. 250-272.
A.G. Chapman et al., “Anticonvulsant activity of two . . . , ” Neuropharmacology 39 (2000), pp. 1567-1574.
A.G. Chapman et al., “Anticonvulsant actions of LY 367385 . . . ,” European Journal of Pharmacology 368 (1999), pp. 17-24.
Barmore Robert
Delmar Eric G.
Moe Scott T.
Shcherbakova Irina
Sheehan Susan M.
Aulakh Charanjit S.
Birch & Stewart Kolasch & Birch, LLP
NPS Pharmaceuticals Inc.
LandOfFree
Metabotropic glutamate receptor antagonists and their use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabotropic glutamate receptor antagonists and their use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabotropic glutamate receptor antagonists and their use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528439